AstraZeneca signs $6 bln cancer drug deal with DaiichiThe London-listed company said on Monday it would pay Daiichi an upfront payment of $1 billion for DS-1062, a type of antibody drug conjugate (ADC).The logo of AstraZeneca is seen on a medication package in a pharmacy in London April 28, 2014(photo credit: STEFAN WERMUTH/REUTERS)
